4.7 Review

Preclinical models of idiosyncratic drug-induced liver injury (iDILI): Moving towards prediction

期刊

ACTA PHARMACEUTICA SINICA B
卷 11, 期 12, 页码 3685-3726

出版社

INST MATERIA MEDICA, CHINESE ACAD MEDICAL SCIENCES
DOI: 10.1016/j.apsb.2021.11.013

关键词

Drug-induced liver injury; Preclinical models; Mechanisms; Oxidative stress; Mitochondrial damage; Immune response; Personalized medicine

资金

  1. Instituto de Salud Carlos III (Spain) [PI18/01804, PI19-00883, PT20/00127, UMA18-FEDERJA-194, PY18-3364, CD21/00198]
  2. Consejeria de Salud de Andalucia (Spain) [CD21/00198, PEMP-0127-2020]
  3. Ministerio de Ciencia del Gobierno de Espana [IJCI-2017-31466]
  4. COST (European Cooperation in Science and Technology) [CA17112]

向作者/读者索取更多资源

Idiosyncratic drug-induced liver injury (iDILI) is a major public health concern with a lack of biomarkers for prediction, diagnosis, and prognosis, highlighting the need for new models to study and predict its mechanisms. Current preclinical assessment methods have limitations in correlating hepatotoxicity markers with clinically significant iDILI, prompting the exploration of alternative approaches for improved accuracy in predicting iDILI.
Idiosyncratic drug-induced liver injury (iDILI) encompasses the unexpected harms that prescription and non-prescription drugs, herbal and dietary supplements can cause to the liver. iDILI remains a major public health problem and a major cause of drug attrition. Given the lack of biomarkers for iDILI prediction, diagnosis and prognosis, searching new models to predict and study mechanisms of iDILI is necessary. One of the major limitations of iDILI preclinical assessment has been the lack of correlation between the markers of hepatotoxicity in animal toxicological studies and clinically significant iDILI. Thus, major advances in the understanding of iDILI susceptibility and pathogenesis have come from the study of well-phenotyped iDILI patients. However, there are many gaps for explaining all the complexity of iDILI susceptibility and mechanisms. Therefore, there is a need to optimize preclinical human in vitro models to reduce the risk of iDILI during drug development. Here, the current experimental models and the future directions in iDILI modelling are thoroughly discussed, focusing on the human cellular models available to study the pathophysiological mechanisms of the disease and the most used in vivo animal iDILI models. We also comment about in silico approaches and the increasing relevance of patient-derived cellular models. (C) 2021 Chinese Pharmaceutical Association and Institute of Materia Medica, Chinese Academy of Medical Sciences. Production and hosting by Elsevier B.V.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据